Manila Times Business
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program
Management Believes the Company is Entering a Transformative Stage with a Novel, First-In-Class Cancer Therapy for Treatment & Prevention of Metastatic Cancer from Solid Tumors MELBOURNE, Australia, June 11, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc” or the "Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced it has approved a share repurchase program authori
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Ambros Therapeutics Appoints Cris Calsada as Chief Financial Officer and Claire Padgett, Ph.D., as SVP of Clinical Operations and Program Management
2h ago
Manganese X Energy to Present at the June 16 Energy & Precious Metals Virtual Investor Summit
2h ago
Energy & Precious Metals Virtual Investor Summit Agenda Announced for June 16th
2h ago
WatchMatic Highlights Market Trends Influencing Luxury Watch Investment Strategies
2h ago